Last reviewed · How we verify
Experimental: CRH administration
Experimental: CRH administration is a Small molecule drug developed by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. It is currently FDA-approved.
CRH administration was studied in a clinical trial as an experimental intervention for various conditions, including hypopituitarism, central diabetes insipidus, panhypopituitarism, psychological disorder, and social isolation. However, the information provided does not match the mechanism of action of CRH, as CRH is not listed in ChEMBL and the information provided in ChEMBL refers to a cyclooxygenase inhibitor, which is unrelated to CRH.
At a glance
| Generic name | Experimental: CRH administration |
|---|---|
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: CRH administration CI brief — competitive landscape report
- Experimental: CRH administration updates RSS · CI watch RSS
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau portfolio CI
Frequently asked questions about Experimental: CRH administration
What is Experimental: CRH administration?
Who makes Experimental: CRH administration?
What development phase is Experimental: CRH administration in?
Related
- Manufacturer: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing